

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

**中國神威藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2877)**

**SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO  
THE AUDITED RESULTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

Reference is made to the announcement of China Shineway Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 29 March 2022 (the “**Announcement**”) in relation to the audited consolidated results of the Group for the year ended 31 December 2021 and declaration of an interim dividend for the year ending 31 December 2022. The Board would like to provide further information in relation to the Announcement. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined used in the Announcement.

After considering the Dividend Policy, the Board does not recommend the payment of any final dividend for the year ended 31 December 2021. Instead, as disclosed in the Announcement, the Company has declared an interim dividend for the year ending 31 December 2022 amounting to RMB21 cents per share (the “**2022 Interim Dividend**”). For details of the 2022 Interim Dividend (including the period for closure of register of members, the record date and the payment date), please refer to the Announcement.

By Order of the Board  
**China Shineway Pharmaceutical Group Limited**  
**Li Zhenjiang**  
*Chairman*

Hong Kong, 30 March 2022

*As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Liu Shun Fai.*